AAAAAA
Results:
1-11
|
Results: 11
Authors:
Di Leo, A
Larsimont, D
Gancberg, D
Jarvinen, T
Beauduin, M
Vindevoghel, A
Michel, J
Focan, C
Ries, F
Gobert, P
Closon-Dejardin, MT
Dolci, S
Rouas, G
Paesmans, M
Lobelle, JP
Isola, J
Piccart, MJ
Citation: A. Di Leo et al., HER-2 and topo-isomerase II alpha as predictive markers in a population ofnode-positive breast cancer patients randomly treated with adjuvant CMF orepirubicin plus cyclophosphamide, ANN ONCOL, 12(8), 2001, pp. 1081-1089
Authors:
Piccart, MJ
Di Leo, A
Beauduin, M
Vindevoghel, A
Michel, J
Focan, C
Tagnon, A
Ries, F
Gobert, P
Finet, C
Closon-Dejardin, MT
Dufrane, JP
Kerger, J
Liebens, F
Beauvois, S
Bartholomeus, S
Dolci, S
Lobelle, JP
Paesmans, M
Nogaret, JM
Citation: Mj. Piccart et al., Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer, J CL ONCOL, 19(12), 2001, pp. 3103-3110
Authors:
Focan, C
Beauduin, M
Salamon, E
de Greve, J
de Wasch, G
Lobelle, JP
Majois, F
Tagnon, A
Tytgat, J
van Belle, S
Vandervellen, R
Vindevoghel, A
Citation: C. Focan et al., Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13years update in a multicentre randomized trial, BR J CANC, 85(1), 2001, pp. 1-8
Authors:
Focan, C
Kreutz, F
Focan-Henrard, D
Moeneclaey, N
Citation: C. Focan et al., Chronotherapy with 5-fluorouracil, folinic acid and carboplatin for metastatic colorectal cancer; an interesting therapeutic index in a phase II trial, EUR J CANC, 36(3), 2000, pp. 341-347
Authors:
Focan, C
Bury, J
Beauduin, M
Herman, ML
Vindevoghel, A
Brohee, D
Lecomte, M
Citation: C. Focan et al., Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial, ANTI-CANC D, 11(7), 2000, pp. 549-554
Authors:
Giacchetti, S
Perpoint, B
Zidani, R
Le Bail, N
Faggiuolo, R
Focan, C
Chollet, P
Llory, JF
Letourneau, Y
Coudert, B
Bertheaut-Cvitkovic, F
Larregain-Fournier, D
Le Rol, A
Walter, S
Adam, R
Misset, JL
Levi, F
Citation: S. Giacchetti et al., Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer, J CL ONCOL, 18(1), 2000, pp. 136-147
Authors:
Cure, H
Chevalier, V
Pezet, D
Bousquet, J
Focan, C
Levi, F
Garufi, C
Chipponi, J
Chollet, P
Citation: H. Cure et al., Phase II trial of chronomodulated infusion of 5-fluorouracil and folinic acid in metastatic colorectal cancer, ANTICANC R, 20(6C), 2000, pp. 4649-4653
Authors:
Focan, C
Bury, J
Beauduin, M
Herman, ML
Vindevoghel, A
Lecomte, M
Brohee, D
Canon, JL
Focan-Henrard, D
Citation: C. Focan et al., Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer, ANTICANC R, 20(6C), 2000, pp. 4665-4672
Authors:
Focan, C
Levi, F
Kreutz, F
Focan-Henrard, D
Lobelle, JP
Adam, R
Dallemagne, B
Jehaes, C
Markiewicz, S
Weerts, J
Bismuth, H
Jasmin, C
Misset, JL
Citation: C. Focan et al., Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion, ANTI-CANC D, 10(4), 1999, pp. 385-392
Authors:
Garufi, C
Dogliotti, L
Terzoli, E
Focan, C
Smaaland, R
Chollet, P
Perpoint, B
Levi, F
Citation: C. Garufi et al., Letter to the Editor, TUMORI, 85(2), 1999, pp. 149-150
Authors:
Levi, F
Zidani, R
Brienza, S
Dogliotti, L
Perpoint, B
Rotarski, M
Letourneau, Y
Llory, JF
Chollet, P
Le Rol, A
Focan, C
Citation: F. Levi et al., A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma, CANCER, 85(12), 1999, pp. 2532-2540
Risultati:
1-11
|